Home Federal Bank of Tennessee Sells 122 Shares of Abbott Laboratories (NYSE:ABT)

Home Federal Bank of Tennessee decreased its stake in Abbott Laboratories (NYSE:ABT) by 0.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 19,547 shares of the healthcare product maker’s stock after selling 122 shares during the period. Abbott Laboratories accounts for about 0.8% of Home Federal Bank of Tennessee’s holdings, making the stock its 21st biggest position. Home Federal Bank of Tennessee’s holdings in Abbott Laboratories were worth $2,593,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Redwood Park Advisors LLC bought a new stake in Abbott Laboratories during the 4th quarter worth approximately $25,000. Noble Wealth Management PBC purchased a new position in Abbott Laboratories in the fourth quarter worth about $26,000. NewSquare Capital LLC grew its stake in shares of Abbott Laboratories by 78.4% in the fourth quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker’s stock worth $27,000 after acquiring an additional 105 shares during the period. WealthTrak Capital Management LLC bought a new stake in shares of Abbott Laboratories in the fourth quarter worth approximately $28,000. Finally, Rialto Wealth Management LLC bought a new stake in Abbott Laboratories during the fourth quarter valued at approximately $29,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 0.1%

Shares of ABT opened at $133.41 on Tuesday. The firm has a market cap of $232.11 billion, a P/E ratio of 17.44, a price-to-earnings-growth ratio of 2.52 and a beta of 0.73. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $141.23. The company’s 50-day moving average price is $130.77 and its 200 day moving average price is $126.01. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. On average, sell-side analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, Director Sally E. Blount sold 2,600 shares of the business’s stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the completion of the sale, the director now owns 34,058 shares in the company, valued at approximately $4,415,960.28. The trade was a 7.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the topic of several research analyst reports. Royal Bank of Canada boosted their target price on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a report on Thursday, April 17th. Bank of America boosted their target price on shares of Abbott Laboratories from $133.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Wall Street Zen downgraded shares of Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 12th. Raymond James upped their price target on shares of Abbott Laboratories from $132.00 to $142.00 and gave the company an “outperform” rating in a research note on Thursday, April 17th. Finally, Barclays upped their price target on shares of Abbott Laboratories from $158.00 to $159.00 and gave the company an “overweight” rating in a research note on Thursday, April 17th. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $142.59.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.